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1Chapter
Prophylaxis of Acute Arthritis 
at Initiation of Urate-Lowering 
Therapy in Gout Patients
Maxim Eliseev, Maria Chikina and Evgeny Nasonov
Abstract
During the first months after the initiation of urate-lowering therapy in gout 
patients, the risk of exacerbation of arthritis considerably rises, which often results 
in discontinuation of the prescribed therapy by patients. The main way to avoid this 
risk is preventive prescription of colchicine, NSAIDs or glucocorticoids. Such pro-
phylaxis of acute arthritis has been specified in a large number of the latest editions 
of various national and international guidelines; however, this tactics is rarely used 
in practice. The chapter includes the most significant studies on this problem.
Keywords: gout, prophylaxis, urate-lowering therapy, NSAID, colchicine, GC, 
canakinumab, acute attack
1. Introduction
It is known that the frequency of gout attacks increases at initiation of any 
medications (allopurinol, febuxostat, PEG-uricase, and benzbromarone) that 
lower serum uric acid level, irrespectively of their mechanism of action [1, 2]. 
The most promising method to reduce the risk of acute arthritis in gout patients 
is to initiate preventive anti-inflammatory drug therapy (NSAIDs, colchicine, or 
glucocorticoids).
The need for preventive therapy of gout flares is also stated in the current 
guidelines [3, 4]. Thus, according to the guidelines by the European League against 
Rheumatism (EULAR), the need for prophylaxis of future gout flares should 
be explained to every patient and discussed with them. As the first-line therapy 
drug, it is recommended to use 0.5–1.0 mg colchicine daily and the dose should be 
lowered if the patient was diagnosed with renal insufficiency. Besides, the authors 
of the guidelines emphasize the need for observing the patients with renal insuf-
ficiency who receive HMG-CoA reductase inhibitors (statins) at the initiation 
of colchicine, considering the potential risks of neuro- and/or muscle toxicity. 
According to the guidelines, simultaneous prescription of colchicine and strong 
P-glycoprotein inhibitors and/or CYP3A4 should be avoided. In cases of intolerance 
to colchicine or contraindications for thereof, it is advised to consider prophylaxis 
with NSAID (also in the minimum effective anti-inflammatory dose, with the use 
of gastroprotective therapy if needed) [3]. The guidelines by the American College 
of Rheumatology (ACR) are similar to those by EULAR, however, according to the 
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Source 
(study)
Type of 
study/trial
Drug Period of 
observation
Number 
of 
patients
Results
Paulus et al., 
1974 [9]
Double-
blind 
placebo-
controlled
Colchicine 
0.5 mg 3 times 
daily
6 months 38 • The patients who received probenecid 
with colchicine had on average 0.19 gout 
flares per month, whereas in the patients 
who received probenecid and placebo, 
the frequency of attacks was on average 
0.48 per month.
Borstad 
et al., 2004 
[1]
Double-
blind 
placebo-
controlled
Colchicine 
0.6 mg twice 
per day
6 months 43 • The patients who had colchicine ther-
apy reported of acute arthritis much 
less often (0.52 vs. 2.91, p = 0.008), 
and in the case of development of acute 
arthritis, the intensity of pain at VAS 
was lower (3.64 vs. 5.08, p = 0.018).
Karimzadeh 
et al., 2006 
[10]
Randomized 
without 
placebo 
control
Colchicine 
1 mg daily
1 year 229 • Basing on the received data, the 
researchers came to the conclusion 
that the optimal length of colchicine 
therapy for prophylaxis of acute 
arthritis is 7–9 months from the start 
of urate-lowering therapy.
Wortmann 
et al., 2010 
[38]
Randomized 
placebo-
controlled
Colchicine 
0.6 mg daily 
or naproxen 
250 mg twice 
a day
6 months 4101 • In the groups where patients received 
colchicine or NSAIDs, they reported of 
reduction of the frequency of acute arthri-
tis during the entire period of therapy, 
irrespectively of the selected medication.
• Immediately after discontinuation of 
the 8-week prophylactic therapy, the 
frequency of acute arthritis increased 
by three times, irrespectively of the 
drug used for prophylaxis.
Jinquan 
et al., 2018 
[45]
Comparative 
retrospective 
placebo-
controlled
Colchicine 
0.53 ± 0.15 mg 
daily or 
prednisolone 
7.55 ± 1.3 mg 
daily
6 months 273 • Gout flares were noted more often 
in the patients who received therapy 
with prednisolone.
• However, the intensity of pain during 
the acute arthritis was higher in the 
patients who received colchicine.
Schlesinger 
et al., 2011 
[47]
Double-
blind 
randomized 
active-
controlled
Canakinumab 
10, 25, 50, 
90, 150 mg, 
one-time or 
triamcinolone 
acetonide 
(TA) 40 mg, 
one-time
8 weeks 200 • The reduction in pain on the 
canakinumab therapy was more 
marked than on TA in 25, 48 and 
72 hours.
• The period between gout flares on 
canakinumab was longer than on TA.
Schlesinger 
et al., 2012 
[48]
Double-
blind 
randomized 
multicenter 
controlled
Canakinumab 
150 mg, 
one-time or 
triamcinolone 
acetonide 
(TA) 40 mg, 
one-time
24 weeks 465 • Reduction of the risk of gouty arthritis 
attacks by 66% in 12 weeks.
• Reduction of the average number of 
new gouty arthritis attacks by 63% in 
12 weeks.
Solomon 
et al., 2018 
[49]
Randomized 
placebo-
controlled
Canakinumab 
50 mg, 150 or 
300 mg once in 
3 months
3.7 years 10,061 • Quarterly reception of canakinumab 
allowed to significantly reduce the risk 
of acute arthritis, irrespectively of the 
serum uric acid level.
Table 1. 
Efficacy of prophylactic anti-inflammatory therapy at initiation of urate-lowering drugs in gout patients.
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latter, in cases of contraindications for NSAID and colchicine, it is possible to initi-
ate low-dose glucocorticoids [4].
Such prophylaxis is recommended to be given for 6 months from the start of 
urate-lowering therapy. This exact tactic allows to not only minimize the risk of 
acute arthritis, but also to reduce probability of self-discontinuation of the urate-
lowering therapy by the patient.
However, the evidence basis for these recommendations is not ample and there 
have been no randomized controlled comparative trials of certain medications.
The most considerable studies on preventive anti-inflammatory therapy at the 
start of urate-lowering drug therapy are presented in Table 1.
2. Colchicine
Colchicine, an alkaloid received from Colchicum autumnale, is the most well-
studied medication used for prophylaxis of acute arthritis at the initiation of 
urate-lowering therapy [5].
The mechanisms by which colchicine has its anti-inflammatory action are 
manifold. Probably the most valuable of these mechanisms is the effect on tubulin 
molecule, which conditions its cytotoxic and anti-inflammatory action due to the 
inhibition of migration, chemotaxis, neutrophil adhesion, as well as the suppression 
of superoxide anion synthesis [5].
The modern data suggest the possibility of the direct anti-inflammatory action 
of colchicine associated with IL-1-stimulated neutrophil adhesion inhibition. It has 
been recently shown that colchicine reducing pro-caspase-1 mRNA and secreted 
caspase-1 protein, an enzymatic component of NLR of the NOD-like receptor 
Pirin-3 (NLRP3) which regulates conversion of pro-interleukin-1β (IL-1β) into 
active IL-1β [6].
In 1961, Yu and Gutman first performed a study to estimate the possibility to use 
low-dose colchicine for exacerbation prophylaxis, which resulted in reduction of 
the frequency of acute arthritis both in the patients who received colchicine mono-
therapy and in those who received colchicine with concurrent probenecid. The 
duration of the therapy was 2–10 years, the patients received 0.5–2.0 mg colchicine 
daily, which was less than the colchicine dose typically used for rapid relief from 
acute arthritis at that time. As a result, the frequency and severity of acute arthritis 
considerably reduced in 74% patients; there were no differences in the frequency in 
the groups of patients who received probenecid and of those who did not, and the 
discontinuation of colchicine caused arthritis exacerbation within several weeks or 
months in 20 out of 25 patients who had not had acute arthritis for several years [7].
In 1965, Gutman published the findings of a retrospective analysis of 734 gout 
patients in which it was stated that reception of colchicine significantly reduced 
frequency of acute arthritis, irrespectively of the chosen urate-lowering therapy [8].
The first placebo-controlled study to show the efficacy of colchicine prophylaxis 
in acute gout arthritis was the study by Paulus et al. [9]. The study involved 51 
gout patients with typical gout flares and serum uric acid level of >7.5 mg/dl. The 
patients were randomized and divided into two groups: probenecid 500 mg and 
colchicine 0.5 mg three times daily, or probenecid 500 mg and a placebo three times 
daily. The analysis included 38 patients who showed significant reduction in their 
average serum uric acid level. During the study, the patients reported about gout 
attacks which were classified as light, moderate and severe, and only those classified 
as moderate and severe were included in the analysis. As a result, during the study 
period, the patients from the probenecid/colchicine group had on average 0.19 gout 
attacks per month, while the patients from the probenecid/placebo group reported 
about on average 0.48 attacks per month.
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In 2004, Borstad et al. [1] carried out the first study to evaluate the efficacy of 
low-dose colchicine at initiation of urate-lowering therapy (allopurinol). The study 
included 43 patients with established gout who began allopurinol therapy. As a gout 
flare prophylaxis, the patients took either colchicine 0.6 mg twice a day or a pla-
cebo, depending on their randomization. Both groups were analogous in their basic 
characteristics and in the doses of allopurinol necessary to reach the target uric 
acid level. The observation period was 6 months. The patients who took colchicine 
reported about gout flares much less often (0.52 vs. 2.91, p = 0.008), and in the 
cases of development of gout flares, the intensity of pain according to VAS was 
lower (3.64 vs. 5.08, p = 0.018). The tolerance of colchicine was good, however, the 
frequency of diarrhea was higher in the patients who took colchicine (38.0% in the 
colchicine patients vs. 4.5% in the placebo patients), and the reduction of the dose 
of colchicine to 0.6 mg once a day leveled those differences almost completely.
The study by Karimzadeh et al. [10] estimated the optimal length of colchicine 
therapy for prophylaxis of acute arthritis in gout patients. 229 patients using the 
allopurinol and colchicine 1 mg daily therapy were randomized into three groups: 
group 1 took colchicine for 3–6 months, group 2 for 7–9 months and group 3 for 
10–12 months. After a one-year observation period, 54% of the patients in group 1, 
27.5% of the patients in group 2, and 23% of the patients in group 3 had at least one 
gout flare. Basing on the received data, it was concluded that the optimal length of 
colchicine treatment for prophylaxis is 7–9 months. However, that study had a num-
ber of limitations as it was not placebo-controlled, the patients only informed about 
the time interval until the flare, not about the number of flares. Besides, the study 
did not provide any information on which criteria had been used to diagnose gout. 
Another important limitation of this study, just like of many others, was absence 
of a clear definition of gout flare for self-assessment by the patient. Recently the 
results of a multicenter work have been published which compared several simple 
ways of self-assessment which, as is expected, can reduce the possibility of making 
mistakes in investigation findings [11].
It is proved that bioavailability of colchicine is the same for elderly and young 
people. However, the distribution volume of colchicine can go down, which leads 
to its higher concentration in plasma and a significantly higher risk of toxicity. To 
counteract this effect, some experts recommend reducing the dose of colchicine by 
two times in the patients over 70 years old [12].
Critics of long reception of colchicine for gout flare prophylaxis at the start 
of urate-lowering therapy discuss how safe this tactics of therapy is. The doses 
of colchicine of 0.5–0.8 mg/kg are highly toxic and the doses over 0.8 mg/kg are 
usually fatal; in order to reduce the risk of irreversible overdose, the US Food and 
Drug Administration called off the permission to use colchicine intravenously [13]. 
Acute overdose of colchicine usually appears as gastrointestinal symptoms within 
24 hours after taking, multiple organ failure (renal insufficiency, circulatory defi-
ciency, bone marrow destruction, muscle weakness, rhabdomyolysis, and respira-
tory failure) within 7 days, and finally ends up with either resolution of symptoms 
or progression of dysfunction of organs and eventual death [14–17].
Chronic overdose of colchicine can arise when daily doses of colchicine are not 
adjusted for renal insufficiency or simultaneous reception of certain medications; 
colchicine neuromyopathy and cytopenia are classical characteristics of chronic 
overdose [14].
Colchicine predominantly binds three proteins: tubulin, Cytochrome P3A4 
(CYP3A4) and P-glycoprotein (Pgp) [18].
CYP3A4 is contained in hepatocytes and enterocytes and metabolizes colchicine 
to 2.3 dimethyl colchicine. P-glycoprotein, which is contained in enterocytes, 
hepatocytes, renal and other cells, limits gastrointestinal absorption of colchicine. 
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Along with renal excretion, these systems determine general level of colchicine 
in blood serum. Individual content of CYP3A4 and P-glycoprotein conditions 
absence of adequate response to colchicine in some patients, which can be associ-
ated with excessive expression of one or both of these proteins [19]. CYP3A4 and 
P-glycoprotein are also responsible for interaction between colchicine and other 
medications. Because of its interaction with CYP3A4, colchicine can have harmful 
effect if simultaneously taken with clarithromycin, fluoxetine, paroxetine and other 
inhibitors of proteases, which are metabolized with the aid of this ferment [20].
Several descriptions of clinical cases and one retrospective review show that 
combination of colchicine and inhibitors of HMG-CoA reductase, which also 
interact with CYP3A4, can sometimes increase the risk of acute myopathy [21–23].
Kuritzky and Panchal debate about advisability and safety of prophylactic 
reception of anti-inflammatory medications at the start of urate-lowering therapy, 
referring to a large number of adverse drug reactions in such a therapy [24]. Under 
discussion is the possibility for the patient to choose between constant therapy dur-
ing average 6 months or rapid relief of flares as required. Also, the authors came to 
the conclusion that long use of colchicine is safer than that of NSAIDs. It was noted 
that myopathy and rhabdomyolysis are registered more often in the cases of high 
doses and simultaneous use with not only HMG-CoA reductase inhibitors (statins) 
but also with fibrates, verapamil, diltiazem, cyclosporine and others, which presup-
poses the need for serious control in case of their simultaneous use.
Kuncl et al. [14] presented a description of 12 new cases of typical syndromes of 
myopathy and neuropathy amid use of colchicine by gout patients. Myopathy usu-
ally appears as proximal weakness and is always accompanied by higher serum level 
of creatine kinase; both appearances remain for at least 3 or 4 weeks after discon-
tinuation of the medication. Accompanying axonal polyneuropathy is usually mild, 
but resolves slowly after discontinuation. Electromyography of proximal muscles 
usually reveals myopathy which is characterized by abnormal spontaneous activity. 
Due to these peculiarities, c-induced myopathy is often diagnosed incorrectly, either 
as probable polymyositis or uremic neuropathy. C-induced myopathy is character-
ized by accumulation of lysosomes and autophagosomes unrelated to necrosis or 
moderate denervation in distal muscles. Morphological changes in muscles indicate 
that pathogenesis relates to damage of microtubular cytoskeletal network which 
interacts with lysosomes. Correct diagnosis can save patients with such a disorder 
from a wrong therapy. Myotoxicity most often arises in people over 50–70 years 
old who take 1.2 mg colchicine daily. Thus, prescription of a long-term colchicine 
therapy for patients over 50 years old should be carried out with maximal caution.
Tolerance to colchicine is dose-dependent and the recommended dose for 
prophylaxis of arthritis (0.6 mg once or twice a day), as a rule, is better tolerable 
than higher doses used earlier to treat acute gout arthritis (1.2 mg at acute flare with 
subsequent increase by 0.6 mg hourly) [25]. The most common colchicine-induced 
adverse drug reactions occur with the gastrointestinal tract, namely nausea and 
diarrhea, which are reported by 5–10% of the patients, even in cases of low-dose 
colchicine [26]. Gastrotoxicity is highly likely to depend on the dose and can be 
reduced by decreasing the dose of colchicine.
Among other adverse drug reactions related to the toxicity of colchicine, we 
should note neuropathy [24], cytopenia (thrombo-, leuko-, pancytopenia, and aplas-
tic anemia), disseminated intravascular coagulation and metabolic acidosis [27, 28].
Fortunately, probability of adverse drug reactions is low, nevertheless in cases 
of long-term treatment with colchicine it is necessary to perform regular analysis of 
clinical blood test, level of creatine phosphokinase, transaminases, which is par-
ticularly important in elderly patients, especially in cases of simultaneous reception 
of some of the abovementioned medications.
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Besides the possibility of prophylaxis of acute gout flares at the initiation of 
urate-lowering medications and titration of their dose, there have been discus-
sions about the favorable effect of colchicine on the cardiovascular system [29]. 
Retrospective cohort studies in patients with gout report a lower incidence of 
combined cardiovascular outcomes in those treated with colchicine [30].
Thus, in the retrospective crossover study Crittenden et al. [31] investigated 
whether use of colchicine relates to reduction of risk of myocardial infarction (MI) 
in gout patients. The primary outcome was diagnostication of MI, the second-
ary outcomes included all-cause mortality and C-reactive protein (CRP) level. 
Altogether 1288 patients were diagnosed with gout. The groups of patients who 
received colchicine (n = 576) and of those who did not (n = 712) were comparable 
in demographic criteria and their serum uric acid level. Prevalence of MI was 1.2% 
in the group who received colchicine, as against 2.6% in the group who did not 
(p = 0.03).
In the next study it was proved that reception of 0.5 mg of colchicine daily in 
addition to the therapy with statins and other medications used for secondary 
prevention of cardiovascular catastrophes, led to reduction of cases of development 
of acute coronary syndrome, out-of-hospital cardiac arrest and ischemic stroke 
[hazard ratio (HR) 0.33; 95% confidence interval (CI) 0.18–0.59; p < 0.001] [32].
Meta-analysis of trials of colchicine in multiple cardiovascular diseases revealed 
a decrease in myocardial infarction with varying levels of evidence [30].
Currently the randomized controlled CONVINCE trial is enrolling stroke 
patients to evaluate the effect of a daily low-dose of colchicine in reducing the rate 
of recurrent stroke and major vascular events [33].
3. NSAIDs
Along with colchicine, NSAIDs are used as the first line drug therapy for acute 
arthritis prophylaxis in gout patients. Just like with colchicine, the history of using 
NSAIDs for gout is centuries old. Thus, among the ancestors of the modern anti-
inflammatory drugs there were vegetable foods containing salicylic acid, such as 
willow bark, meadowsweet, dried raspberries and others [34–36].
At present, there are no works which could determine the optimal dose or dura-
tion of NSAIDs treatment for prophylaxis of acute gout arthritis [37].
Within the frameworks of phase 3 trial on comparison of efficacy of inhibitors 
of xanthine oxidase of allopurinol and febuxostat, the effect of low-dose colchicine 
therapy on the frequency of acute arthritis during the first weeks of urate-lowering 
therapy was assessed. Selection of a certain drug for prophylaxis of acute arthritis 
was performed directly by the doctor. In 79.6% cases they chose colchicine in the 
dose of 0.6 mg daily, in 15.2% cases—NSAIDs (naproxen 250 mg twice a day), and 
the remaining 5.1% patients did not receive prophylactic treatment. In the groups 
where the patients took colchicine or NSAIDs, the frequency of gout attacks dur-
ing the entire period of treatment reduced, irrespectively of the medication. It is 
interesting that immediately after the discontinuation of the 8-week prophylactic 
therapy, the frequency of gout attacked increased by three times irrespectively of 
which medication was used for prophylaxis and remained higher than the original 
during several months of treatment with both xanthine oxidase inhibitors. The 
frequency of unfavorable effects of colchicine treatment (55.1%) was higher than 
that of naproxen (44.3%) (p < 0.001), however, colchicine was used more often 
(selection of the medication was carried out by the researcher, without randomiza-
tion), and in the case of decrease of creatinine clearance <50 ml/min naproxen was 
not prescribed [38].
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These facts explains limitation of long-term use of NSAIDs. Firstly, it relates 
to the increase in the frequency of NSAIDs-related adverse drug reactions from 
the gastrointestinal tract [39]. Secondly, to the need of a considerable part of gout 
patients for acetylsalicylic acid medications.
Besides, NSAIDs should be used with caution in gout patients with lower 
glomerular filtration rate (long use of NSAIDs by such patients is contraindicated) 
because they can lead to acute and chronic renal insufficiency, nephrotic syndrome 
with interstitial nephritis, papillary necrosis, lower clearance of potassium and 
sodium [40].
In 2010, a study was carried out to assess efficacy of urate-lowering therapy with 
allopurinol and febuxostat. During the period from February 2010 to December 
2010, 516 out of 679 respondents were randomly (1:1:1) prescribed febuxostat 
40, 80 mg or allopurinol 300 mg. As prophylactic anti-inflammatory therapy, the 
patients, during the first 8 weeks, received 0.5 mg of colchicine daily or 7.5 mg of 
meloxicam daily. As a result, the number of patients who needed treatment of acute 
gout attacks from the 9th to the 28th week was extremely low: 4.07% (7/172) in the 
group on 80 mg febuxostat, 5.23% (9/172) in the group on 40 mg febuxostat and 
9.3% (16/172) in the group on allopurinol. Besides the considerable reduction of the 
number of acute attacks during the urate-lowering therapy in all groups, the study 
revealed high adherence of patients and low percentage of patients who discontin-
ued urate-lowering therapy (on average 5%), which often related to development of 
unfavorable reactions [41].
Use of NSAIDs also related to increased risk of cardiovascular pathology, which 
makes it even harder to choose a certain medication because every other gout 
patient has a high risk of cardiovascular complications [42].
4. Glucocorticoids
In case of impossibility to prescribe NSAIDs or colchicine and/or their inefficacy 
for prophylaxis of acute arthritis in gout patients, it is proposed to prescribe low-
dose glucocorticoids, however, there is little data on their long-term therapy in gout 
patients [43].
It is thought that prescription of low-dose prednisolone can be efficient and 
safer than NSAIDs for treatment of acute arthritis in gout patients. However, there 
have been no randomized controlled trials aimed at investigating comparative 
efficacy of glucocorticoids and NSAIDs [44].
So far, the first and only comparative study of efficacy of colchicine and glucocor-
ticoids at the initiation of urate-lowering therapy, namely febuxostat therapy, is the 
study by Yu et al. [45]. The study included 273 patients, where 152 patients received 
colchicine as acute arthritis prophylactic therapy, 49 received prednisolone, and the 
remaining 72 patients did not receive any anti-inflammatory medications. The mean 
daily dosage of febuxostat in the groups of patients receiving colchicine, glucocor-
ticoids and in the control group was 41.97 ± 10.74, 40.82 ± 9.09, and 41.67 ± 9.93 mg 
daily respectively. The mean daily dosage of colchicine was 0.53 ± 0.15 mg daily, 
the duration of therapy 6.13 ± 1.14 months. The mean daily dosage of prednisolone 
was 7.55 ± 1.30 mg daily, the duration of therapy was 6.20 ± 1.36 months. The target 
serum uric acid level of <360 μmol/l was achieved in each group. No severe ADRs 
were noted. The analysis of the data showed that acute arthritis attacks were reported 
271 times altogether, where 46 attacks (21.7%) in the colchicine group, 47 (44.9%) 
in the glucocorticoids group and 178 (91.7%) in the control group. However, at high 
frequency of recurrent gouty arthritis, the intensity of pain during acute arthritis 
was lower in the patients who received glucocorticoids therapy.
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5. Canakinumab
A considerable part of gout patients have contraindications for NSAID, colchicine 
and glucocorticoids, and often such therapy can be ineffective, especially in patients 
with severe tophaseous gout, which implies the need for using other methods of 
therapy. For such patients, it is advisable to consider the use of IL-1 inhibitors, at 
least the use of long half-life medications (in particular IL-1β: canakinumab).
Among possible methods of prophylaxis, use of IL-1 inhibitors can be discussed, 
at least use of medications with long half-life (in particular IL-1β: canakinumab). 
Use of the medication in gout patients is limited to solely rapid relief of arthritis 
resistant to any other anti-inflammatory therapy or in case of its impossibility. 
However, the steady anti-inflammatory effect of the medication, which surpasses 
that of both colchicine and glucocorticoids, allows to initiate therapy with urate-
lowering drugs and perform titration of the dose of allopurinol with minimal risk 
of development of acute arthritis [46, 47].
Within the framework of a 24-week phase 2 trial, the efficacy of different doses 
of canakinumab and colchicine was compared in 432 gout patients [46]. The plans 
of therapy determined by randomization included subcutaneous injections of 25, 
50, 100, 200 or 300 mg of canakinumab on the first day or four injections with 
four-week intervals (50 mg on the first day and in the fourth week and 25 mg on the 
eighth and twelfth weeks) or daily reception of colchicine 0.5 mg per os daily during 
16 weeks. It was established that the average number of gout attacks was lower with 
any dose of canakinumab, with maximal of 100–300 mg. In the cases of the use of 
canakinumab doses of ≥50 mg, the average number of attacks was lower by 62–72% 
than in the case of colchicine, and the risk of at least one attack was lower by 64–72%.
The two following 12-week double-blind multicenter controlled trials of 
phase 3 carried out with the same design and united for analysis (β-RELIEVED 
and β-RELIEVED II) compared the efficacy of 150 mg canakinumab and 40 mg 
triamcinolone acetonide (TA) as a means of prophylaxis of acute arthritis [48]. 
Canakinumab significantly increased the period between attacks and reduced the 
risk of recurrent gouty arthritis (by 63% in 12 weeks and by 56% in 24 weeks). 
Moreover, the median time period between attacks for canakinumab was 168 days, 
which exceeded the duration of the trial (24 weeks).
In their study Solomon et al. [49] compared the frequency of gout attacks at 
the initiation of urate-lowering therapy in patients with different original serum 
uric acid levels (≤404.5, 404.6–535.3, and ≥ 535.4 μmol/l). As prophylaxis of gout 
flares they used canakinumab in different doses (50, 150, and 300 mg), which 
was injected subcutaneously every 3 months. The observation period was almost 
4 years and after analyzing the received data it was found that quarterly injection 
of canakinumab was associated with a significantly lower risk of acute arthritis, 
irrespectively of the serum uric acid level.
Canakinumab therapy is generally well-tolerated, although all the studies associ-
ated the use of canakinumab with the increase in infectious adverse drug reactions 
(ADR), including severe ones. The probability of ADR was comparable for any of 
the used doses of canakinumab (51.9–58.5%) and colchicine (53.7%) [46]. Most 
of the ADR were light or moderate, and severe ADR were registered in 14 (4.3%) 
patients receiving canakinumab and six (5.6%) patients receiving colchicine. All 
six cases of severe ADR in four patients were registered in the canakinumab group. 
In another phase 2 trial, the total frequency of ADR was also comparable (41.3% in 
the canakinumab group and 42.1% in the TA group) with the frequency of severe 
ADR (2.8 and 1.8% respectively) [50]. The only case of infectious bronchitis was 
registered in the canakinumab group, but, from the researchers’ point of view, it was 
unlikely to be associated with the reception of the drug. Finally, in the phase 3 trials 
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united for the analysis, where the dose of canakinumab was one-time 150 mg, the 
differences in the frequency of ADR (66.2% in the canakinumab group and 52.8% in 
the TA group) were conditioned by infectious ADR, mainly non-severe infections of 
upper airways (20.4% in the canakinumab group and 12.2% in the TA group) [48].
None of the studies registered fatal cases associated with infectious diseases. Although 
the use of canakinumab was accompanied by moderate reduction of the levels of throm-
bocytes, leucocytes and neutrophils in the blood, it did not have clinical relevance.
Canakinumab therapy should be carried out by a rheumatologist experienced in 
gout treatment and genetically biological disease modifying antirheumatic drugs 
(bDMARDs). Before the start of the therapy, it is important to exclude active and 
latent tuberculosis infections. The recommended dose of canakinumab is 150 mg 
(subcutaneously). If there is need for a repeated injection, the interval between 
the two should be over 12 weeks. In case of no effect after the first injection, it is 
inadvisable to give repeated injections.
6. Conclusion
To summarize, it should be noted that neglect of recommendations on prophy-
laxis of acute arthritis during the first months of urate-lowering therapy, despite the 
Figure 1. 
Acute arthritis prophylaxis algorithm at initiation of urate-lowering therapy in gout patients. *There are no 
recommendations for use of canakinumab for prophylaxis of acute arthritis, however, it can be effective at 
initiation of urate-lowering therapy in patients with severe tophaceous gout and frequent gout flares [48, 49].
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firm guidelines of its necessity, is one of the most common mistakes in treatment 
of gout [51]. For example, according to the analysis of the database of 643 gout 
patients who were first prescribed allopurinol, only 26% were also prescribed pro-
phylactic anti-inflammatory therapy (16% received NSAIDs and 10%—colchicine) 
[52]. At that, besides the burden of pain and poorer working ability which result 
from acute arthritis, this exact mistake can be the main cause of patient’s discon-
tinuation of urate-lowering medications and patient’s low adherence to treatment. 
As a result—development of chronic arthritis, formation of tophi, as well as gouty 
arthropathy and bone tissue destruction. One of the ways to avoid the above said is 
to adhere to the recommendations on gout treatment whose integral part is prophy-
laxis of acute arthritis at the initiation of urate-lowering medications. The suggested 
algorithm of the drug prophylaxis of acute arthritis during the first months of 
urate-lowering therapy presupposes sequential selection of the anti-inflammatory 
medication (see Figure 1). As the first-line medication, it is advised to use colchi-
cine, in cases of contraindications for or poor tolerance to thereof—NSAID, and 
if NSAID therapy is not possible either—glucocorticoids. Finally, for the patients 
with chronic arthritis and the need for regular use of anti-inflammatory drugs, it is 
possible to consider IL-1 inhibitors (canakinumab).
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